Early buyers will receive 10% customization on this report.
Rising R&D expenditure and increasing focus on drug discovery are the major factors driving the adoption of discovery informatics solutions.
Based on function, the sequencing and target data analysis segment is accounted for the largest share of the market in 2017
On the basis of function, the drug discovery informatics market is divided into sequencing and target data analysis, docking, molecular modeling, libraries & database preparation, and other functions. In 2017, the sequencing and target data analysis segment is expected to account for the largest share of the drug discovery informatics market.
Factors such as the expansive application of informatics solutions in targeted analysis and the large amount of data generated during the drug discovery process are driving the growth of this segment.
Based on solution, the software segment is accounted for the largest share of the market in 2017
The solution segment of the drug discovery informatics market is divided into software and services. In 2017, the software segment is expected to account for the largest share of the global drug discovery informatics market. The dominant share of this market is attributed to the fact that drug discovery informatics software solutions enable the fast and efficient management of data generated throughout the drug discovery process.
North America is expected to dominate the market in 2017
The North America is expected to account for the largest share of the drug discovery informatics market in 2017. Established pharmaceutical industry with the presence of leading pharmaceutical and biotechnology companies attributes to the largest share of North America. Europe is expected to account for the second-largest share of the drug discovery informatics market.
The key players operating in the drug discovery informatics market are IBM (US), Infosys (India), Schrödinger (US), PerkinElmer (US), and Thermo Fisher Scientific (US).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
